O
CRNX icon

OrbiMed’s Crinetics Pharmaceuticals CRNX Stock Holding History

OrbiMed’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$4.17M – 115
2025
Q3 		$4.17M Buy
+100,000
New +$3.2M 0.1% 91

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's CRNX Position: Q2 2026 in Review

OrbiMed held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 999,000 shares worth $37.4M. The position accounts for 0.69% of the portfolio, ranked #43.

OrbiMed first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $90.8M in Q4 2021. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • OrbiMed held 999,000 shares of Crinetics Pharmaceuticals worth $37.4M as of Q2 2026.
  • OrbiMed left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.69% of OrbiMed's portfolio in Q2 2026, its #43 holding.
  • OrbiMed first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • OrbiMed's Crinetics Pharmaceuticals position peaked at $90.8M in Q4 2021.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.